HIV Breakthrough Setback: Latest News & Research
- The quest for an effective HIV vaccine has hit a snag as mRNA HIV vaccine trials are experiencing setbacks.
- Julie McElrath, head of the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center, believes mRNA technology remains crucial for HIV vaccine development.
- Kimberly Blumenthal, an allergist and immunologist at Massachusetts General hospital, noted the severity of chronic hives, impacting patients' ability to work.
HIV vaccine research faces significant hurdles.mRNA HIV vaccine trials are on pause due to unexpected skin reactions like chronic hives, a setback impacting progress. Federal funding cuts further complicate the situation for researchers striving to find solutions.Despite these challenges, experts like Julie McElrath stress the crucial role of mRNA technology. While some trials show promise, a concerning number of participants experienced rashes. News Directory 3 provides insights into the impact of these changes on the fight against HIV and shares perspectives on vaccine safety. The road ahead involves research into alternative dosage levels and vaccine formulas aiming to balance efficacy with minimizing adverse effects. Discover what’s next in the ongoing battle.
mRNA HIV Vaccine trials Halted Amid Skin Reactions, Funding Cuts
Updated May 31, 2025
The quest for an effective HIV vaccine has hit a snag as mRNA HIV vaccine trials are experiencing setbacks. Researchers are grappling with unexpected skin reactions, including chronic hives, in some participants. These complications, coupled with recent funding cuts, threaten to derail progress in this critical area of medical research.
Julie McElrath, head of the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Center, believes mRNA technology remains crucial for HIV vaccine development. Several mRNA-based HIV vaccines are currently in clinical trials, showing early promise in eliciting key immune responses. However, recent trials have revealed a concerning side affect: a notable percentage of participants developing rashes and chronic hives after receiving Moderna-manufactured vaccines.
These skin reactions, while treatable, can be debilitating. Kimberly Blumenthal, an allergist and immunologist at Massachusetts General hospital, noted the severity of chronic hives, impacting patients’ ability to work. The unusual frequency of these reactions has prompted researchers to slow down mRNA HIV vaccine research to investigate the underlying cause, according to William Schief, a biophysicist at Scripps Research Institute.
The situation is further intricate by changes in federal support. Secretary of Health and Human Services robert F. Kennedy Jr. has voiced concerns about mRNA vaccine safety, leading to funding cuts for HIV and vaccine research. Emily Hilliard, HHS’s press secretary, stated that mRNA technology remains ”under-tested,” justifying the department’s decision to shift priorities.
Several researchers expressed concern about the current climate, fearing that public association with mRNA vaccines could jeopardize their funding. This surroundings, they argue, stifles open discussion and hinders progress toward ending the HIV pandemic.
John Moore, an HIV researcher and vaccinologist at Cornell, confirmed the rashes are a “real, confirmed, generalizable” side effect. Genevieve Fouda, an immunologist and HIV researcher also at Cornell, expressed concern that the discomfort caused by chronic hives could deter individuals from completing the vaccine series.
Robert Paris, a vice president at Moderna, acknowledged that the observed hive rates are an “outlier.” Jim Kublin, director of HVTN, noted that other HIV Vaccine Trials Network vaccines, including non-Moderna mRNA vaccines, have not shown similar rash rates.
“Unless we can find a substitute source of support, this work won’t go forward,” said Barton Haynes, a Duke immunologist.
What’s next
Despite the challenges, researchers remain optimistic. They are exploring strategies such as tweaking vaccine recipes and combining mRNA technology with other approaches. A trial in South Africa will test lower vaccine doses to minimize side effects.The ultimate goal is to strike a balance between minimizing adverse reactions and generating a robust immune response to combat HIV.